BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

53 articles for WK Hagmann

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding.EBI
Merck Sharp and Dohme Research Laboratories
Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids.EBI
TBA
Design and Synthesis of Novel, Selective GPR40 AgoPAMs.EBI
Merck Research Laboratories
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.EBI
Merck
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.EBI
Merck Research Laboratories
Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists.EBI
Merck Research Laboratories
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.EBI
Merck Research Laboratories
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists.EBI
Merck Research Laboratories
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists.EBI
Merck Research Laboratories
N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.EBI
Merck Research Laboratories
N-aryl 2,6-dimethoxybiphenylalanine analogues as VLA-4 antagonists.EBI
Merck Research Laboratories
Identification of unique VLA-4 antagonists from a combinatorial library.EBI
Merck Research Laboratories
N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.EBI
Merck Research Laboratories
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.EBI
TBA
Conformational analysis and receptor docking of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (taranabant, MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist.EBI
Merck Research Laboratories
Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.EBI
Merck Research Laboratories
Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.EBI
Merck Research Laboratories
Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant.EBI
Merck Research Laboratories
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.EBI
Merck Research Laboratories
 
Orally active inhibitors of stromelysin-1 (MMP-3)EBI
TBA
 
Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptidesEBI
TBA
 
Phosphinic acid inhibitors of matrix metalloproteinasesEBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'EBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalaninesEBI
TBA
 
Inhibition of interleukin-1β converting enzyme by N-acyl-aspartyl aryloxymethyl ketonesEBI
TBA
 
Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acidsEBI
TBA
 
The effect of N-acyl substituents on the stability of monocyclic β-lactam inhibitors of human leukocyte elastaseEBI
TBA
Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.EBI
Merck Research Laboratories
1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.EBI
Merck Research Laboratories
The many roles for fluorine in medicinal chemistry.EBI
Merck Research Laboratories
Discovery of N-{(1S,2S)-2-(3-cyanophenyl)- 3-[4-(2-[18F]fluoroethoxy)phenyl]-1-methylpropyl}- 2-methyl-2-[(5-methylpyridin-2-yl)oxy]propanamide, a cannabinoid-1 receptor positron emission tomography tracer suitable for clinical use.EBI
TBA
Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists.EBI
Merck Research Laboratories
Highly constrained bicyclic VLA-4 antagonists.EBI
Merck Research Laboratories
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical Candidates.EBI
Merck
Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases.EBI
Merck Research Laboratories
Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.EBI
Merck Research Laboratories
Amidines as amide bond replacements in VLA-4 antagonists.EBI
Merck Research Laboratories
N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.EBI
Merck Research Laboratories
Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.EBI
Merck Research Laboratories
N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.EBI
Merck Research Laboratories
N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.EBI
Merck Research Laboratories
Substituted tetrahydrofuroyl-1-phenylalanine derivatives as potent and specific VLA-4 antagonists.EBI
Merck Research Laboratories
Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.EBI
Merck Research Laboratories
The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.EBI
Merck Research Laboratories
The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.EBI
Merck Research Laboratories
Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins.EBI
Merck Research Laboratories
The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.EBI
Merck Research Laboratories
Substituted imidazoles as glucagon receptor antagonists.EBI
Merck Research Laboratories
Substituted 2-aminopyridines as inhibitors of nitric oxide synthases.EBI
Merck Research Laboratories
Design, synthesis and biological evaluation of indane derived GPR40 agoPAMs.EBI
Merck
Potent, orally absorbed glucagon receptor antagonists.EBI
Merck Research Laboratories
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.EBI
Merck Research Laboratories